Robert A Copeland

List of Publications by Year
in descending order

20	5,358	567281 15	839539 18
papers	citations	h-index	g-index

25	25	25	8081
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. Biochemistry, 2021, 60, 2275-2284.	2.5	2
2	Evolution of the drug-target residence time model. Expert Opinion on Drug Discovery, 2021, 16, 1441-1451.	5.0	25
3	Special Issue on Epigenetics: Targeting Chromatin- and RNA- Modifications. ACS Medicinal Chemistry Letters, 2020, 11, 2051-2052.	2.8	0
4	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncology, The, 2018, 19, 649-659.	10.7	450
5	The Elements of Translational Chemical Biology. Cell Chemical Biology, 2018, 25, 128-134.	5.2	16
6	RNA-modifying proteins as anticancer drug targets. Nature Reviews Drug Discovery, 2018, 17, 435-453.	46.4	107
7	Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170080.	4.0	34
8	Drug Discovery and Chemical Biology of Cancer Epigenetics. Cell Chemical Biology, 2017, 24, 1120-1147.	5.2	47
9	The drugâ€“target residence time model: a 10-year retrospective. Nature Reviews Drug Discovery, 2016, 15, 87-95.	46.4	540
10	Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics, 2014, 13, 842-854.	4.1	457
11	Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2. ACS Chemical Biology, 2014, 9, 2459-2464.	3.4	29
12	Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis. Analytical Biochemistry, 2011, 416, 206-210.	2.4	82
13	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20980-20985.	7.1	608
14	Residence Time of Receptorâ^'Ligand Complexes and Its Effect on Biological Function. Biochemistry, 2008, 47, 5481-5492.	2.5	469
15	A Second p53 Binding Site in the Central Domain of Mdm2 Is Essential for p53 Ubiquitination. FASEB Journal, 2007, 21, A273.	0.5	0
16	Drugâ€“target residence time and its implications for lead optimization. Nature Reviews Drug Discovery, 2006, 5, 730-739.	46.4	1,237
17	A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7625-7630.	7.1	112
18	A method for determining intracellular concentrations of enzyme substrates from a combination of competitive inhibition and mutagenesis studies. Analytical Biochemistry, 2005, 337, 351-353.	2.4	2

#	Article	IF	Citations
19	Mechanism of Inhibition of Human KSP by Monastrol:Â Insights from Kinetic Analysis and the Effect of Ionic Strength on KSP Inhibitionâ€. Biochemistry, 2004, 43, 15258-15266.	2.5	52
20	Mechanistic considerations in high-throughput screening. Analytical Biochemistry, 2003, 320, 1-12.	2.4	151